Amoéba (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the signature of a Material Transfer Agreement (MTA) with Bayer, a global enterprise with core competencies in the Life Science fields of health care and agriculture. The purpose of this partnership is to evaluate the performance of Amoéba's biocontrol solutions and, if tests are conclusive, could lead to a possible business development partnership.
Bayer wishes to test, through its research partnership with Amoéba, biocontrol solutions containing the amoeba lysate Willaertia magna C2c Maky.
These trials, conducted by the Crop Science division, in accordance with Bayer internal procedures, will be carried out on various pathogens affecting crops.
"Because crops protection must be associated with the environment and populations safeguard, Amoéba has demonstrated, through several partnerships latest signings, the validity of its research to offer new natural alternatives. The evaluation phases of our biocontrol products are scaling up through these research agreements with major players in the sector, who could become our customers if tests are conclusive.” explains Fabrice Plasson, Chairman and CEO of Amoéba.
Amoéba points out that the company is still in the testing phase for its biocide and biocontrol applications and does not currently market any products.
